To amend title XVIII of the Social Security Act to exempt certain drugs from the part D manufacturer discount program under the Medicare program.
Latest Action
Referred to the Subcommittee on Health.
Official Summary
Official summary has not been imported yet.
GovScope Watchdog™
AI Government Intelligence™This bill proposes an amendment to title XVIII of the Social Security Act to exempt certain drugs from the Part D manufacturer discount program under Medicare. The Part D manufacturer discount program currently requires drug manufacturers to provide discounts on certain drugs to reduce out-of-pocket costs for Medicare beneficiaries. By exempting specific drugs from this discount requirement, the bill aims to modify how discounts are applied within the Medicare Part D program.
The bill seeks to change Medicare Part D rules by exempting certain drugs from manufacturer discount requirements, potentially affecting drug pricing and program costs.
- Amends title XVIII of the Social Security Act, which governs Medicare.
- Exempts certain drugs from the Part D manufacturer discount program.
- Currently, manufacturers provide discounts on drugs to reduce costs for Medicare beneficiaries; this bill changes that framework for specified drugs.
['Pharmaceutical manufacturers of the exempted drugs, who may no longer be required to provide discounts under Part D.', 'Potentially Medicare Part D plan sponsors depending on how the exemption affects program costs and pricing.']
['The bill text is not provided, so the scope of the exemption and its financial impact on Medicare and beneficiaries is unclear.', 'Exempting drugs from manufacturer discounts could increase out-of-pocket costs for some Medicare beneficiaries or increase program expenditures.', 'Oversight and enforcement mechanisms related to the exemption are not detailed, raising questions about implementation.']
The bill was introduced in the House during the 118th Congress and referred to the Subcommittee on Health. It is currently listed as failed or expired, indicating it did not advance to become law. The Medicare Part D program and drug pricing are ongoing topics of legislative interest.
Hidden impact flags detected: 2
GovScope reviewed 2 policy-risk categories. Hover for a quick definition. Click detected flags for bill-specific details.
['Potential increase in drug prices for Medicare beneficiaries if manufacturer discounts are reduced or eliminated for exempted drugs.', "Possible shifts in pharmaceutical manufacturers' pricing strategies in response to changes in discount obligations.", 'Changes in Medicare Part D plan costs that could affect premiums or coverage options.']
The bill lacks a publicly available full text and official summary, limiting transparency about the specific drugs affected and the detailed policy mechanisms. Oversight considerations include monitoring the financial impact on Medicare and beneficiaries and ensuring clear implementation guidelines if enacted.
GovScope Intelligence Roadmap
Future bill intelligence will connect sponsors, committee referrals, related votes, campaign finance, disclosures, and stock trades into one legislative intelligence view.